A recent meta-analysis sheds light on how newer diabetes medications, particularly SGLT2 inhibitors and GLP-1 agonists, can significantly reduce the risk of cardiovascular events in people with type 2 diabetes. These findings emphasize the importance of personalized treatment, considering factors like age and sex for enhanced cardiovascular outcomes.
Diabetes affects over 537 million adults globally, with the majority living with type 2 diabetes. While some individuals can manage their blood glucose levels through diet and exercise, many require medications, especially when insulin resistance becomes pronounced.
Medications for type 2 diabetes, such as metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors, work to control blood sugar levels in different ways. GLP-1 agonists and SGLT2 inhibitors stand out in the latest research for their cardiovascular benefits, in addition to their ability to lower blood glucose.
The Journal of the American Medical Association published a study reviewing over 600 clinical trials that investigated the efficacy of these medications, revealing that both SGLT2 inhibitors and GLP-1 agonists are associated with reduced major cardiovascular events, including heart attacks, strokes, and death. However, the drugs’ effects varied across different patient demographics, particularly age.
Dr. Cheng-Han Chen, an interventional cardiologist, highlighted that both SGLT2 inhibitors and GLP-1 agonists lower cardiovascular disease risk by improving key factors like blood sugar control, blood pressure, weight loss, and blood vessel function. Nevertheless, the impact on cardiovascular events is more pronounced in older patients, especially with SGLT2 inhibitors, despite these drugs showing a lesser effect on blood glucose in this age group.
The meta-analysis found that while all three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — effectively lower hemoglobin A1c, only SGLT2 inhibitors and GLP-1 agonists showed consistent cardiovascular and kidney-related benefits. SGLT2 inhibitors were more effective in younger individuals, while GLP-1 agonists proved more beneficial in older adults, with stronger effects in women.
Dr. Peter Hanlon, a senior research fellow at the University of Glasgow, pointed out that, although the blood glucose-lowering effects of SGLT2 inhibitors diminish in older adults, these medications still provide significant cardiovascular benefits. The efficacy of GLP-1 agonists in older individuals, on the other hand, is less affected by aging processes.
The study suggests that healthcare providers should consider a patient’s age and gender when prescribing these diabetes medications. While SGLT2 inhibitors show greater cardiovascular benefits for older patients, GLP-1 agonists may offer superior protection for younger adults, particularly women.
These findings underscore the growing trend of personalized medicine, emphasizing the need for tailored approaches to diabetes management based on individual characteristics. Clinicians are encouraged to weigh factors like treatment goals, the potential for weight loss, and the cardiovascular risk profiles of patients when selecting appropriate treatments.
Related topics:
Hormone Adrenomedullin Linked to Insulin Resistance in Obesity-Related Diabetes
FDA Warns Diabetes App Users: Missed Alerts Could Lead to Dangerous Health Risks
Ketone Drink Improves Heart Health in People with Type 2 Diabetes, New Study Reveals
